#Mezzion
LightNews LightNews
newsen.bsky.social
Mezzion Receives Encouraging Pre-IND Feedback from FDA on Udenafil for ADPKD#South_Korea#Seoul#ADPKD#Udenafil#Mezzion_Pharma
Mezzion Receives Encouraging Pre-IND Feedback from FDA on Udenafil for ADPKD
Mezzion Pharma's latest news highlights positive FDA feedback regarding their investigational drug, udenafil, for treating autosomal dominant polycystic kidney disease (ADPKD).
third-news.com
May 7, 2026 at 2:51 PM
newsen.bsky.social
Mezzion Pharmaceuticals Gains Funding to Advance Clinical Trials for Fontan Patients#United_States#Fort_Lee#Fontan_Patients#Mezzion_Pharma#JURVIGO
Mezzion Pharmaceuticals Gains Funding to Advance Clinical Trials for Fontan Patients
Mezzion Pharmaceuticals has successfully secured strategic financing to further its Phase 3 FUEL-2 trial aimed at treating Fontan patients, showcasing dedication to this underserved community.
third-news.com
May 14, 2026 at 11:17 AM
newsen.bsky.social
Promising In Vivo Results for Udenafil Highlight Mezzion's Advances in ADPKD Treatment#South_Korea#Seoul#ADPKD#Udenafil#Mezzion_Pharma
Promising In Vivo Results for Udenafil Highlight Mezzion's Advances in ADPKD Treatment
Mezzion Pharma showcases positive in vivo results for udenafil in treating ADPKD, involving significant kidney and heart improvements. This marks a strong move forward in treatment options.
third-news.com
August 2, 2026 at 3:21 PM
kidneystories.bsky.social
Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD - Morningstar - goo.gl/alerts/KomS5q #GoogleAlerts
Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
goo.gl
August 3, 2026 at 2:09 PM
drtimos.bsky.social
Signal or noise? > Mezzion Reports Positive In Vivo Results for Udenafil in
ADPKD >> Comment below! #industry40 #IoT #mhealth #AI #healthtech
Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
Seoul, Korea, Aug. 2, 2026 /PRNewswire/ — Mezzion Pharma Co., Ltd. today announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD). In a preclinical ADPKD model, udenafil reduced kidney cyst burden and blood urea nitrogen (BUN), a blood marker …
dlvr.it
August 2, 2026 at 3:52 PM
l2plabs.bsky.social
Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
Seoul, Korea, Aug. 2, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. today announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD). In a preclinical ADPKD model, udenafil...
dlvr.it
August 2, 2026 at 3:16 PM
l2plabs.bsky.social
FUEL FALD Study Published in Pediatric Cardiology
Peer-reviewed publication advances understanding of Fontan-associated liver disease (FALD) and adds to the growing body of evidence supporting udenafil in Fontan circulation FORT LEE, N.J., July 16, 2026 /PRNewswire/ -- Mezzion Pharmaceuticals today announced publication of "The FUEL FALD...
dlvr.it
July 16, 2026 at 1:09 PM
pressreleasecc.com
Single Ventricle Heart Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma
Single Ventricle Heart Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma – PressReleaseCC
Single Ventricle Heart Disease Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma
www.pressreleasecc.com
January 17, 2026 at 1:45 PM
pressreleasecc.com
Single Ventricle Heart Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion
Single Ventricle Heart Disease Market Set To Grow Substantially Through 2034, DelveInsight Projects | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion | PressReleaseCC
 
www.pressreleasecc.com
June 22, 2025 at 6:12 PM
liliumf.bsky.social
🇸🇦 🇸🇦 🔥 دراسة المرحلة الثالثة لـ Mezzion Pharma تواصل مسارها دون تغييرات - Investing.com

👉 اضغط هنا لقراءة المقال كاملاً 👇

#Mezzion #Pharma #Investing.com
دراسة المرحلة الثالثة لـ Mezzion Pharma تواصل مسارها دون تغييرات - Investing.com
news.google.com
June 6, 2026 at 12:12 PM
longtail-news.bsky.social
Feed: "FinSMEs"
Published on Wednesday, June 11, 2025
Mezzion Pharmaceuticals Receives $20M in Strategic Funding
Mezzion Pharma, a Seoul, South Korea-based company developing clinical development programs, raised approximately $20M USD in strategic funding
www.finsmes.com
June 12, 2025 at 8:48 AM
longtail-news.bsky.social
Feed: "openPR.com - Newsfeed"
By: DelveInsight Business Research LLP on Thursday, May 22, 2025
Single Ventricle Heart Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Mezzion, Gene Techno Science, Longerevon
Single Ventricle Heart Disease emerging therapies such as Udenafil JRM 001 and others are expected to boost the Single Ventricle Heart Disease Market in the upcoming years DelveInsight has launched a new report on Single Ventricle Heart Disease Market Insights ...
www.openpr.com
May 22, 2025 at 2:30 PM
longtail-news.bsky.social
Feed: "ABNewswire"
By: admin on Wednesday, May 21, 2025
Single Ventricle Heart Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Mezzion Pharma, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion
The Key Single Ventricle Heart Disease Companies in the market include – Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others.   DelveInsight’s “Single Ventricle Heart Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers … Continue reading →
www.abnewswire.com
May 21, 2025 at 7:41 PM
patesalo-e.bsky.social
Mezzion Pharmaceuticals, Inc Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients - MarketScreener: Mezzion Pharmaceuticals, Inc Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients  MarketScreener
Mezzion Pharmaceuticals, Inc Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients - MarketScreener
Mezzion Pharmaceuticals, Inc Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients  MarketScreener
news.google.com
December 3, 2025 at 5:03 PM
patesalo-e.bsky.social
Mezzion Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients - PR Newswire: Mezzion Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients  PR Newswire
Mezzion Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients - PR Newswire
Mezzion Announces U.S. Patent Allowance Strengthening Udenafil Exclusivity in Fontan Patients  PR Newswire
news.google.com
December 3, 2025 at 2:03 PM
newsen.bsky.social
Mezzion Pharma Achieves Critical Phase 3 Milestone for Udenafil Therapy#South_Korea#Seoul#Udenafil#Mezzion_Pharma#FUEL-2
Mezzion Pharma Achieves Critical Phase 3 Milestone for Udenafil Therapy
Mezzion Pharma has successfully completed a major regulatory milestone with their FUEL-2 study, assessing udenafil for rare heart diseases. The study continues as planned.
third-news.com
June 5, 2026 at 12:08 PM
newsen.bsky.social
Mezzion Pharmaceuticals Celebrates New Legislation Aimed at Improving Pediatric Care#USA#Fort_Lee#Mezzion_Pharmaceuticals#Give_Kids_a_Chance#Mikaela_Naylon
Mezzion Pharmaceuticals Celebrates New Legislation Aimed at Improving Pediatric Care
Mezzion Pharmaceuticals expresses gratitude for the passing of the Mikaela Naylon Give Kids a Chance Act, enhancing pediatric drug development.
third-news.com
February 4, 2026 at 2:37 PM
newsen.bsky.social
Mezzion Pharmaceuticals Welcomes Dr. Ridwan Shabsigh as New COO to Lead Rare Disease Innovations#USA#Fort_Lee,_NJ#JURVIGO#Mezzion#Ridwan_Shabsigh
Mezzion Pharmaceuticals Welcomes Dr. Ridwan Shabsigh as New COO to Lead Rare Disease Innovations
Dr. Ridwan Shabsigh has been appointed as Mezzion Pharmaceuticals' COO, bringing over 35 years of expertise in drug development and clinical research critical for advancing JURVIGO®.
third-news.com
January 6, 2026 at 2:46 PM
newsen.bsky.social
Mezzion Secures Key U.S. Patent for Udenafil Benefitting Fontan Patients#United_States#Fort_Lee#Mezzion_Pharmaceuticals#Udenafil#Fontan_Patients
Mezzion Secures Key U.S. Patent for Udenafil Benefitting Fontan Patients
Mezzion Pharmaceuticals has received a crucial U.S. patent for Udenafil, boosting its exclusivity for Fontan patients and paving the way for future advancements.
third-news.com
December 3, 2025 at 2:56 PM
newsen.bsky.social
Mezzion Pharmaceuticals Celebrates Major Enrollment Achievement in Fontan Clinical Research#South_Korea#Seoul#Mezzion_Pharmaceuticals#JURVIGO#Fontan_population
Mezzion Pharmaceuticals Celebrates Major Enrollment Achievement in Fontan Clinical Research
Mezzion Pharmaceuticals marks a significant milestone in its FUEL-2 trial. Targeting adolescents with Fontan circulation, the study aims to improve treatment options for this vulnerable community.
third-news.com
July 31, 2025 at 12:19 PM
newsen.bsky.social
Mezzion Pharma Ventures into ADPKD Market with Udenafil Pipeline Expansion#South_Korea#Seoul#ADPKD#Udenafil#Mezzion_Pharma
Mezzion Pharma Ventures into ADPKD Market with Udenafil Pipeline Expansion
Mezzion Pharma is expanding its udenafil pipeline into ADPKD, targeting a lucrative market for kidney disease treatment, aiming for safer and effective options.
third-news.com
June 12, 2025 at 1:40 PM
newsen.bsky.social
Mezzion Pharma Announces $20 Million Funding to Support Udenafil for Fontan Patients' Trials#South_Korea#Seoul#Udenafil#Fontan_Patients#Mezzion_Pharma
Mezzion Pharma Announces $20 Million Funding to Support Udenafil for Fontan Patients' Trials
Mezzion Pharmaceuticals secures $20 million in funding to advance development of udenafil, targeting Fontan patients' unmet needs.
third-news.com
June 11, 2025 at 1:33 PM
newsen.bsky.social
New ICD-10 Codes Enhance Care for Fontan-Associated Conditions in Heart Disease#South_Korea#Seoul#Mezzion_Pharmaceuticals#Fontan#ICD-10_Codes
New ICD-10 Codes Enhance Care for Fontan-Associated Conditions in Heart Disease
Mezzion Pharmaceuticals announces new ICD-10 codes aimed at better recognition and treatment of Fontan-associated conditions, advancing care in rare heart diseases.
third-news.com
April 16, 2025 at 2:48 PM